The phase 3 CAIRO3 study showed that capecitabine plus bevacizumab (CAP-B) maintenance treatment after six cycles capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) in metastatic colorectal cancer (mCRC) patients is effective, without compromising quality of life. In this post hoc analysis with updated follow-up and data regarding sidedness, we defined subgroups according to RAS/BRAF mutation status and mismatch repair (MMR) status, and investigated their influence on treatment efficacy.

中文翻译：

---

卡培他滨和贝伐单抗的维持治疗与转移性大肠癌的观察：CAIRO3 3期研究的最新结果和分子亚组分析

CAIRO3的3期研究表明，卡培他滨联合贝伐单抗（CAP-B）六个疗程后，卡培他滨，奥沙利铂和贝伐单抗（CAPOX-B）在转移性结直肠癌（mCRC）患者中是有效的，而不会影响生活质量。在本次事后分析中，采用了最新的随访资料和有关偏侧性的数据，我们根据RAS / BRAF突变状态和错配修复（MMR）状态定义了亚组，并研究了它们对治疗效果的影响。